OBJECTIVES:Amphetamine improves vigilance as assessed by continuous performance tests (CPT) in children and adults with attention deficit hyperactivity disorder (ADHD). Less is known, however, regarding amphetamine effects on vigilance in healthy adults. Thus, it remains unclear whether amphetamine produces general enhancement of vigilance or if these effects are constrained to the remediation of deficits in patients with ADHD. METHODS: We tested 69 healthy adults (35 female) on astandardized CPT (Conner's CPT-2) after receiving 10- or 20-mg d-amphetamine or placebo. To evaluate potential effects on learning, impulsivity, and perseveration, participants were additionally tested on the Iowa Gambling Task (IGT) and Wisconsin Card Sorting Task (WCST). RESULTS: Participants receiving placebo exhibited the classic vigilance decrement, demonstrated by a significant reduction in attention (D') across the task. This vigilance decrement was not observed, however, after either dose of amphetamine. Consistent with enhanced vigilance, the 20-mg dose also reduced reaction time variability across the task and the ADHD confidence index. The effects of amphetamine appeared to be selective to vigilance since no effects were observed on the IGT, WCST, or response inhibition/perseveration measures from the CPT. CONCLUSIONS: The present data support the premise that amphetamine improves vigilance irrespective of disease state. Given that amphetamine is a norepinephrine/dopamine transporter inhibitor and releaser, these effects are informative regarding the neurobiological substrates of attentional control. (JINS, 2018, 24, 283-293).
RCT Entities:
OBJECTIVES:Amphetamine improves vigilance as assessed by continuous performance tests (CPT) in children and adults with attention deficit hyperactivity disorder (ADHD). Less is known, however, regarding amphetamine effects on vigilance in healthy adults. Thus, it remains unclear whether amphetamine produces general enhancement of vigilance or if these effects are constrained to the remediation of deficits in patients with ADHD. METHODS: We tested 69 healthy adults (35 female) on a standardized CPT (Conner's CPT-2) after receiving 10- or 20-mg d-amphetamine or placebo. To evaluate potential effects on learning, impulsivity, and perseveration, participants were additionally tested on the Iowa Gambling Task (IGT) and Wisconsin Card Sorting Task (WCST). RESULTS:Participants receiving placebo exhibited the classic vigilance decrement, demonstrated by a significant reduction in attention (D') across the task. This vigilance decrement was not observed, however, after either dose of amphetamine. Consistent with enhanced vigilance, the 20-mg dose also reduced reaction time variability across the task and the ADHD confidence index. The effects of amphetamine appeared to be selective to vigilance since no effects were observed on the IGT, WCST, or response inhibition/perseveration measures from the CPT. CONCLUSIONS: The present data support the premise that amphetamine improves vigilance irrespective of disease state. Given that amphetamine is a norepinephrine/dopamine transporter inhibitor and releaser, these effects are informative regarding the neurobiological substrates of attentional control. (JINS, 2018, 24, 283-293).
Authors: Jeffery N Epstein; C Keith Conners; Aaron S Hervey; Simon T Tonev; L Eugene Arnold; Howard B Abikoff; Glen Elliott; Laurence L Greenhill; Lily Hechtman; Kimberly Hoagwood; Stephen P Hinshaw; Betsy Hoza; Peter S Jensen; John S March; Jeffrey H Newcorn; William E Pelham; Joanne B Severe; James M Swanson; Karen Wells; Benedetto Vitiello; Timothy Wigal Journal: J Child Psychol Psychiatry Date: 2006-05 Impact factor: 8.982
Authors: Nicholas J Cooper; Hannah Keage; Daniel Hermens; Leanne M Williams; David Debrota; C Richard Clark; Evian Gordon Journal: J Integr Neurosci Date: 2005-03 Impact factor: 2.117
Authors: Ajna Hamidovic; Andrea Dlugos; Andrew Skol; Abraham A Palmer; Harriet de Wit Journal: Exp Clin Psychopharmacol Date: 2009-12 Impact factor: 3.157
Authors: Arpi Minassian; Jared W Young; Zackary A Cope; Brook L Henry; Mark A Geyer; William Perry Journal: Psychopharmacology (Berl) Date: 2015-10-09 Impact factor: 4.530
Authors: Nina Pocuca; Jared W Young; David A MacQueen; Scott Letendre; Robert K Heaton; Mark A Geyer; William Perry; Igor Grant; Arpi Minassian Journal: Drug Alcohol Depend Date: 2020-08-22 Impact factor: 4.492
Authors: David A MacQueen; Arpi Minassian; Johnny A Kenton; Mark A Geyer; William Perry; Jonathan L Brigman; Jared W Young Journal: Neuropharmacology Date: 2018-05-31 Impact factor: 5.250
Authors: Savita G Bhakta; James F Cavanagh; Jo A Talledo; Juliana E Kotz; Lindsay Benster; Benjamin Z Roberts; John A Nungaray; Jonathan L Brigman; Gregory A Light; Neal R Swerdlow; Jared W Young Journal: Neuropsychopharmacology Date: 2022-01-18 Impact factor: 8.294
Authors: Elizabeth B de Sousa Fernandes Perna; Eef L Theunissen; Patrick C Dolder; Natasha L Mason; Nadia R P W Hutten; Stefan W Toennes; Kim P C Kuypers; Johannes G Ramaekers Journal: Front Pharmacol Date: 2018-07-06 Impact factor: 5.810